Hepatitis A, D, E
HEPATITIS A
Definition:
A hepatotrophic virus; the liver is the primary site of infection, replication and cellular damage
Epidemiology:
Undeveloped countries: Africa, Asia, etc. In U.S., most are predominant in western states (especially American Indians)
Causes 40% of cases of acute viral hepatitis in the U.S.
Etiologies:
Transmission: fecal-oral route; contaminated food, water, shellfish; day-care center outbreaks
HAV is the most infectious and transmittable viral hepatitis of all viral hepatitis
Incubation: 2-6 weeks
Pathophysiology:
Virus: RNA, linear gene shape, no envelope, 28 nm in size
Clinical Manifestations/Physical Exam:
Natural History: anorexia, nausea, vomiting, fatigue, abdominal pain, mild fever, jaundice, dark urine, light stools
Children, especially under age 14, rarely have symptoms
Laboratory Studies:
Treatments:
Treatment of acute HAV is supportive
Vaccine: Children 1-18 yrs (daycare), travelers to endemic areas, military, male-male sex, IVDA, cirrhosis any cause (50% mortality with HAV)
VAQTA or HAVRIX: Adults, 1 ml (50 U) at time 0 and 6 months
Children, 0.5 ml (25 U) at time 0 and 6-18 months
Sufficient serum level post immunization (not established, only advised): >20 mIU/ml; Vaccine doesn’t compromise other vaccines given at same time; If given 1st dose, 2nd dose can be given any time within 5 years and still achieve immunity; 100% show immunity at 12 years
IVIG: No role for pre-exposure prophylaxis, just start vaccination processes; Ok for short-term immunity or children who can’t take vaccine
IVIG dose: Dose 0.02 ml/kg for <3 months protection, 0.06 ml/kg q 5 months for longerStay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree